A patient with metastatic BRAF-mutated colorectal cancer initially responded to combined EGFR and BRAF inhibition with panitumumab plus vemurafenib. Pre-existing cells with increased MET gene copy number in the archival tumor tissue likely underwent clonal expansion during treatment, leading to the emergence of MET amplification in the rebiopsy taken at progression. In BRAF-mutated colorectal cancer cells, ectopic expression of MET conferred resistance to panitumumab and vemurafenib, which was overcome by combining BRAF and MET inhibition. Based on tumor genotyping and functional in vitro data, the patient was treated with the dual ALK-MET inhibitor crizotinib plus vemurafenib, thus switching to dual MET and BRAF blockade, with rapid and marked effectiveness of such strategy. Although acquired resistance is a major limitation to the clinical efficacy of anticancer agents, the identification of molecular targets emerging during the first treatment may afford the opportunity to design the next line of targeted therapies, maximizing patient benefit.

MET-driven resistance to dual EGFR and BRAF blockade may be overcome by switching from EGFR to MET inhibition in BRAF mutated colorectal cancer

ODDO, DANIELE;BARAULT, LUDOVIC;SIRAVEGNA, GIULIA;BARDELLI, Alberto;DI NICOLANTONIO, Federica
Last
2016

Abstract

A patient with metastatic BRAF-mutated colorectal cancer initially responded to combined EGFR and BRAF inhibition with panitumumab plus vemurafenib. Pre-existing cells with increased MET gene copy number in the archival tumor tissue likely underwent clonal expansion during treatment, leading to the emergence of MET amplification in the rebiopsy taken at progression. In BRAF-mutated colorectal cancer cells, ectopic expression of MET conferred resistance to panitumumab and vemurafenib, which was overcome by combining BRAF and MET inhibition. Based on tumor genotyping and functional in vitro data, the patient was treated with the dual ALK-MET inhibitor crizotinib plus vemurafenib, thus switching to dual MET and BRAF blockade, with rapid and marked effectiveness of such strategy. Although acquired resistance is a major limitation to the clinical efficacy of anticancer agents, the identification of molecular targets emerging during the first treatment may afford the opportunity to design the next line of targeted therapies, maximizing patient benefit.
6
9
963
971
http://cancerdiscovery.aacrjournals.org/content/6/9/963.long
BRAF, colorectal cancer, drug resistance, MET
Pietrantonio, Filippo; Oddo, Daniele; Gloghini, Annunziata; Valtorta, Emanuele; Berenato, Rosa; Barault, Ludovic; Caporale, Marta; Busico, Adele; Morano, Federica; Gualeni, Ambra Vittoria; Alessi, Alessandra; Siravegna, Giulia; Perrone, Federica; Di Bartolomeo, Maria; Bardelli, Alberto; de Braud, Filippo; Di Nicolantonio, Federica
File in questo prodotto:
File Dimensione Formato  
Pietrantonio_CD-16-0297_PostPrint_4aperto.pdf

Accesso aperto con embargo fino al 20/06/2017

Descrizione: Articolo principale e dati supplementari
Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 2.21 MB
Formato Adobe PDF
2.21 MB Adobe PDF Visualizza/Apri
Pietrantonio_CancerDiscovery_PDF_editoriale&SI.pdf

Accesso riservato

Descrizione: PDF Editoriale
Tipo di file: PDF EDITORIALE
Dimensione 5.3 MB
Formato Adobe PDF
5.3 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1591711
Citazioni
  • ???jsp.display-item.citation.pmc??? 39
  • Scopus 70
  • ???jsp.display-item.citation.isi??? 71
social impact